Stockscreener 앱 받기
3.59
5.53%
-0.21
시장 영업 전:
3.58
-0.010
-0.28%
전일 마감가:
$3.80
열려 있는:
$3.79
하루 거래량:
1.60M
Relative Volume:
1.11
시가총액:
$1.22B
수익:
$787.89M
순이익/손실:
$20.56M
주가수익비율:
61.37
EPS:
0.0585
순현금흐름:
$96.54M
1주 성능:
+9.79%
1개월 성능:
+21.69%
6개월 성능:
+64.68%
1년 성능:
+2.57%
1일 변동 폭
$3.565
$3.81
1주일 범위
$3.23
$3.89
52주 변동 폭
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
명칭
Goodrx Holdings Inc
전화
(855) 268-2822
주소
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, TEM, HQY, TXG
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
3.59 | 1.30B | 787.89M | 20.56M | 96.54M | 0.0585 |
VEEV
Veeva Systems Inc
|
241.51 | 38.43B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
59.68 | 11.45B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
54.61 | 10.05B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
105.50 | 8.83B | 1.34B | 230.70M | 440.96M | 2.6695 |
TXG
10 X Genomics Inc
|
57.75 | 7.62B | 638.78M | -22.66M | 122.18M | -0.1744 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2026-01-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-08-11 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | 개시 | Mizuho | Neutral |
| 2024-08-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-02-26 | 개시 | Leerink Partners | Outperform |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-08-10 | 업그레이드 | DA Davidson | Neutral → Buy |
| 2023-07-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | 개시 | Citigroup | Buy |
| 2022-11-04 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-08-12 | 개시 | DA Davidson | Neutral |
| 2022-06-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-06-06 | 재개 | BofA Securities | Buy |
| 2022-06-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | 개시 | Wells Fargo | Equal Weight |
| 2022-04-07 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Neutral |
| 2022-03-15 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | 재확인 | Barclays | Overweight |
| 2022-03-01 | 재확인 | BofA Securities | Neutral |
| 2022-03-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-01 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | 재확인 | Evercore ISI | Outperform |
| 2022-03-01 | 재확인 | Goldman | Buy |
| 2022-03-01 | 재확인 | JP Morgan | Underweight |
| 2022-03-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-03-01 | 재확인 | SVB Leerink | Outperform |
| 2022-01-07 | 개시 | Goldman | Buy |
| 2021-12-21 | 개시 | Stephens | Overweight |
| 2021-12-02 | 개시 | Jefferies | Buy |
| 2021-08-31 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-08-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | 개시 | Robert W. Baird | Neutral |
| 2021-04-06 | 재개 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Guggenheim | Buy |
| 2020-11-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | 개시 | Barclays | Equal Weight |
| 2020-10-19 | 개시 | BofA Securities | Neutral |
| 2020-10-19 | 개시 | Citigroup | Buy |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-10-19 | 개시 | Credit Suisse | Outperform |
| 2020-10-19 | 개시 | Deutsche Bank | Hold |
| 2020-10-19 | 개시 | Goldman | Neutral |
| 2020-10-19 | 개시 | JP Morgan | Neutral |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
| 2020-10-19 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | 개시 | SVB Leerink | Outperform |
| 2020-10-19 | 개시 | UBS | Buy |
모두보기
Goodrx Holdings Inc 주식(GDRX)의 최신 뉴스
GoodRx Holdings (GDRX) Could Be 13% Overvalued After Q2 Earnings and Guidance Raise - Yahoo Finance
GoodRx (GDRX) Q2 2026 Earnings Call Transcript - AOL.com
GoodRx (NASDAQ:GDRX) Trading Down 5.1%What's Next? - marketbeat.com
GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope (NASDAQ:GDRX) - Seeking Alpha
GDRX Maintained by Citigroup -- Price Target Raised to $5.00 - GuruFocus
GoodRx (NASDAQ:GDRX) Stock Price Expected to Rise, Citigroup Analyst Says - marketbeat.com
GDRX Maintained by TD Cowen -- Price Target Raised to $5.00 - GuruFocus
GDRX Q2 Deep Dive: Pharma Direct and Subscription Growth Drive Upgraded Outlook - Yahoo Finance
GOODRX HOLDINGS, INC. : CITIGROUP RAISES TARGET PRICE TO $5 FROM $4 - Bitget
GDRX Maintains Overweight by Wells Fargo -- Price Target Raised to $5.00 - GuruFocus
GoodRx Holdings Price Target Raised to $5.00/Share From $3.50 by Wells Fargo - Moomoo
Prescription savings giant GoodRx could be opening office at The Pearl - The Business Journals
GoodRx Holdings Inc (GDRX) Stock Analysis & Forecast - TradingKey
GoodRx Holdings Inc (GDRX) Stock News Today - TradingKey
Wells Fargo & Company Boosts GoodRx (NASDAQ:GDRX) Price Target to $5.00 - marketbeat.com
GoodRx Holdings Inc (GDRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GoodRx Holdings, Inc. Stock 12‑Month Price Target Raised to $3.7 - tradingview.com
Morgan Stanley Adjusts Price Target on GoodRx to $4 From $3, Maintains Equalweight Rating - marketscreener.com
GoodRx (GDRX) Stock Jumps As Margins Strengthen And User Declines Linger - Sahm
Earnings call transcript: GoodRx lifts 2026 outlook after Q2 revenue beat - Investing.com Canada
Transcript : GoodRx Holdings, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
GoodRx Lets Customers Shop Where They Want, CEO Says - marketscreener.com
GoodRx Q2 Earnings Call Highlights - marketbeat.com
GoodRx (NASDAQ:GDRX) Stock Price Up 15.7%Here's Why - marketbeat.com
GDRX: Pharma Direct and subscriptions drove Q2 outperformance, leading to raised 2026 guidance - tradingview.com
GoodRx Holdings, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
GDRX Looks 42.2% Undervalued on GF Value™ - GuruFocus
GDRX SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
GoodRx (NASDAQ:GDRX) Posts Earnings Results, Hits Estimates - marketbeat.com
GoodRx Holdings, Inc. (GDRX) Q2 Earnings Match Estimates - Yahoo Finance
GoodRx (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Is GoodRx Holdings Inc (GDRX) Undervalued After Q2 Earnings? EPS - GuruFocus
GoodRx (NASDAQ:GDRX) Reports Upbeat Q2 CY2026, Stock Soars - Barchart.com
GoodRx Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Aug 05 (Reuters)GoodRx Holdings Q2 Revenue - Moomoo
GDRX: Pharma Direct and subscription growth drove raised 2026 guidance despite lower transactions - tradingview.com
GoodRx Holdings, Inc. (GDRX) Reports In-Line Q2 EPS; Offers Guidance - StreetInsider
GoodRx Reports Second Quarter 2026 Results - marketscreener.com
GoodRx Holdings, Inc. 2026: Revenue $200.41M, EPS $0.02— 10-Q Summary - tradingview.com
GoodRx Holdings (NASDAQ: GDRX) elevates Justin Fengler to CFO role - Stock Titan
GoodRx Holdings (NASDAQ: GDRX) pivots as Rx revenue falls 26% - Stock Titan
GoodRx Holdings, Inc. Announces Management Changes - marketscreener.com
GoodRx Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
GoodRx (NASDAQ: GDRX) Q2 2026 revenue hits $200M as mix shifts - Stock Titan
BRIEF-GoodRx Holdings Q2 Adjusted Net Income USD 26.8 Million Vs. IBES Estimate USD 27.2 Million - tradingview.com
GoodRx Holdings, Inc. Raises Earnings Guidance for the Year 2026 - marketscreener.com
GoodRx earnings up next: Can subscriptions reverse revenue slide? - Investing.com
GoodRx earnings up next: Can subscriptions reverse revenue slide? By Investing.com - Investing.com Nigeria
GDRX Q2'26 Earnings: EPS estimate is 0.08 USD - tradingview.com
GoodRx Earnings: What To Look For From GDRX - Barchart.com
Akebia Therapeutics And 2 Promising Penny Stocks To Watch - simplywall.st
Goodrx Holdings Inc (GDRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Goodrx Holdings Inc 주식 (GDRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| REY-GIRAUD AGNES | Director |
Mar 12 '26 |
Option Exercise |
0.47 |
192,185 |
90,327 |
277,633 |
| Spectrum Equity VII, L.P. | 10% Owner |
Oct 15 '25 |
Sale |
4.00 |
23,771 |
95,103 |
0 |
1.05%
2.00%
자본화:
|
볼륨(24시간):